RE:RE:RE:RE:Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 BillionThe reality is that Big Pharma is facing a looming patent cliff which they address by acquiring late-stage de-risked biological assets/companies, like ONCY biological-platform technology in pelareorep, through premium M&A deals. And Big Pharma has approximately US$1.5 Trillion in "fire-power" to put to work to acquire late-stage biological companies will benefit from the 13 years of FDA market exclusivity that the Inflation Reduction Act (IRA) has outlined.
The "other-hand" reality is that there are posters on this message who bring nothing of value here and instead bring the kind of c%#p that comes with their other-hand stuff.